Anti-p53 FITC

Anti-p53 FITC
Regulatory status
RUO
Antigen
p53
Clone
BP53-12
Format
FITC
Reactivity
Human, Non-human primates
Application
Excitation laser
blue (488 nm)
Variant
0.1 mg
1F-114-C100
In stock
210.00 USD

0.025 mg
1F-114-C025
Delivery 1 week
105.00 USD
Variant
0.1 mg
11-261-C100
In stock
210.00 USD

0.1 mg
11-261-C100
In stock
105.00 USD
Product details
Description
Images
References
Isotype
Mouse IgG2a
Specificity
The antibody BP53-12 recognizes a defined epitope (aa 16-25) on human p53, a 50 kDa intracellular tumour suppressor found in increased amounts in a wide variety of transformed cells; it is frequently mutated or inactivated in many types of cancer.
Application
Application details
Flow cytometry: Recommended dilution: 3 μg/ml. Intracellular staining.
Reactivity
Human, Non-human primates
Immunogen
Bacterially expressed full-length wild-type p53
Concentration
1 mg/ml
Preparation
The purified antibody is conjugated with fluorescein isothiocyanate (FITC) under optimum conditions. The conjugate is purified by size-exclusion chromatography.
Formulation
Phosphate buffered saline (PBS) solution with 15 mM sodium azide
Storage and handling
Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Other names
BCC7, TRP53, TP53, LFS1
Antigen description
The tumour suppressor protein p53 is a key element of intracellular anticancer protection. It mediates cell cycle arrest or apoptosis in response to DNA damage or to starvation for pyrimidine nukleotides. It is up-regulated in response to these stress signals and stimulated to activate transcription of specific genes, resulting in expression of p21waf1 and other proteins involved in G1 or G2/M arrest, or proteins that trigger apoptosis, such as Bcl-2. The structure of p53 comprises N-terminal transactivation domain, central DNA-binding domain, oligomerisation domain, and C-terminal regulatory domain. There are various phosphorylation sites on p53, of which the phosphorylation at Ser15 is important for p53 activation and stabilization.
Entrez Gene ID 7157
UniProt ID P04637
1F-114 FC
Separation of Ramos cells stained using anti-p53 (BP53.12) FITC antibody (concentration in sample 9 μg/ml, red) from unstained Ramos cells (black) in flow cytometry analysis (intracellular staining).

General references:

Agarwal ML, Agarwal A, Taylor WR, Stark GR: p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8493-7.
PubMed
Agarwal ML, Agarwal A, Taylor WR, Chernova O, Sharma Y, Stark GR: A p53-dependent S-phase checkpoint helps to protect cells from DNA damage in response to starvation for pyrimidine nucleotides. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14775-80.
PubMed
Taylor WR, DePrimo SE, Agarwal A, Agarwal ML, Schönthal AH, Katula KS, Stark GR: Mechanisms of G2 arrest in response to overexpression of p53. Mol Biol Cell. 1999 Nov;10(11):3607-22.
PubMed
Taylor WR, Agarwal ML, Agarwal A, Stacey DW, Stark GR: p53 inhibits entry into mitosis when DNA synthesis is blocked. Oncogene. 1999 Jan 14;18(2):283-95.
PubMed
Tanigawa S, Fujii M, Hou DX: Stabilization of p53 is involved in quercetin-induced cell cycle arrest and apoptosis in HepG2 cells. Biosci Biotechnol Biochem. 2008 Mar;72(3):797-804.
PubMed

Product specific references:

Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV, Lane DP: Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene. 1991 Sep;6(9):1699-703.
PubMed
Bartkova J, Bartek J, Lukas J, Vojtesek B, Staskova Z, Rejthar A, Kovarik J, Midgley CA, Lane DP: p53 protein alterations in human testicular cancer including pre-invasive intratubular germ-cell neoplasia. Int J Cancer. 1991 Sep 9;49(2):196-202.
PubMed
Rössner P Jr, Binková B, Chvátalová I, Srám RJ: Acrylonitrile exposure: the effect on p53 and p21(WAF1) protein levels in the blood plasma of occupationally exposed workers and in vitro in human diploid lung fibroblasts. Mutat Res. 2002 May 27;517(1-2):239-50.
PubMed
Dolezalova H, Vojtesek B, Kovarik J: Epitope analysis of the human p53 tumour suppressor protein. Folia Biol (Praha). 1997;43(1):49-51.
PubMed
Variant
0.1 mg
1F-114-C100
In stock
210.00 USD

0.025 mg
1F-114-C025
Delivery 1 week
105.00 USD
Variant
0.1 mg
11-261-C100
In stock
210.00 USD

0.1 mg
11-261-C100
In stock
105.00 USD

Related products

-134%
CloneMOPC-173
Reg. statusRUO
ApplicationFC, FC(IC)
0.1 mg
150.00 USD